Entera Bio Ltd. Research and Development (R&D) Expenses Growth

Research and Development (R&D) Expenses Growth of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Research and Development (R&D) Expenses Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Research and Development (R&D) Expenses Growth for the quarter ending June 29, 2020 was 42.32% (a -300.28% decrease compared to previous quarter)
  • Year-over-year quarterly Research and Development (R&D) Expenses Growth decreased by -3912.61%
  • Annual Research and Development (R&D) Expenses Growth for 2019 was -15.48% (a -107.45% decrease from previous year)
  • Twelve month Research and Development (R&D) Expenses Growth ending June 29, 2020 was 0.81% (a -106.96% decrease compared to previous quarter)
Trailing Research and Development (R&D) Expenses Growth for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19
0.81% -11.63% -15.48%
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Research and Development (R&D) Expenses Growth of Entera Bio Ltd.

Most recent Research and Development (R&D) Expenses Growthof ENTX including historical data for past 10 years.

Interactive Chart of Research and Development (R&D) Expenses Growth of Entera Bio Ltd.

Entera Bio Ltd. Research and Development (R&D) Expenses Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 42.32% -21.13%
2019 -4.33% -1.11% -19.94% -29.66% -15.48%
2018 207.73%

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.